1 June 2018 - If approved, Aimovig (erenumab) is expected to be the first and only available therapy designed specifically for migraine prevention in the EU.

Novartis today announced the CHMP of the EMA has recommended approval for Aimovig (erenumab) for the prevention of migraine in adults who have at least four migraine days per month. The World Health Organization has listed migraine as one of the top ten causes of years lived with disability worldwide. 

Aimovig is the first treatment of its kind specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor, which plays a critical role in migraine. If approved, Aimovig will be self-administered once every four weeks via an auto-injector pen.

Read Novartis press release